Loading
companiesCompany
Shanghai Bovax Biotechnology
Shanghai Bovax Biotechnology is a China-based biotechnology company that leads 4 cancer trials in OnCo, testing quadrivalent, 9-valent and 15-valent HPV vaccines in penile cancer, cervical cancer, vulvar cancer, vaginal cancer and advanced solid tumours.
Also called: Bovax上海博唯生物
Overview
Shanghai Bovax Biotechnology develops recombinant protein vaccines and drugs, with quadrivalent, 9-valent and 15-valent HPV vaccine candidates and a recombinant enterovirus 71 vaccine in clinical development. It runs research in Shanghai and a vaccine manufacturing base in Chongqing through its subsidiary Chongqing Bovax Biopharmaceutical. On ClinicalTrials.gov it is the lead sponsor of 4 trials recorded in OnCo (3 in phase 3 or 2/3): NCT06465914 (phase 3, A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent H...), NCT04422366 (phase 3, Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in...), NCT05027776 (phase 3, Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subject...) and NCT06756269 (phase 2, To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chine...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shanghai, CN
Scorecard
All companies#199of 1244 companies, score 28
- approved products +6
- modalities +2
- regions +2
- registry trials +18
1 approved, 0 in phase 3, 0 earlier, 0 targets, 77 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Founded
2012
ApprovedRecombinant virus-like particle vaccine
Gardasil was the first HPV vaccine, licensed in 2006 to prevent cervical and other genital cancers and genital warts. It has been replaced in most countries by the nine-type version, Gardasil 9.
Similar pages
- TechnologyCancer interception vaccines
Shares A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males, Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females, HPV quadrivalent vaccine (types 6, 11, 16 and 18).
- JournalJournal of gynecologic oncology
Shares Vaginal cancer, Vulvar cancer, Cervical cancer.
- TreatmentNonavalent HPV vaccine
Shares HPV quadrivalent vaccine (types 6, 11, 16 and 18), Penile cancer, Vaginal cancer, Vulvar cancer.
- CompanyFrantz Viral Therapeutics
Shares Vaginal cancer, Vulvar cancer.
- CancerVaginal squamous cell carcinoma (HPV-associated)
Shares Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years, Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females, Vaginal cancer.
- TreatmentHPV bivalent vaccine (types 16 and 18)
Shares HPV quadrivalent vaccine (types 6, 11, 16 and 18), Cervical cancer.
- CancerLocalised penile cancer (organ-confined, node-negative)
Shares A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males, Penile cancer.
- TermHPV status (HPV-positive / HPV-negative)
Shares Penile cancer, Vaginal cancer, Cervical cancer.
cancers
drugs
ApprovedRecombinant virus-like particle vaccine
trials
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese MalesEvaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesImmunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 YearsTo Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years